National Jewish Health Announces Call for Abstracts For Respiratory Disease Young Investigators’ Forum

DENVER, May 23, 2019 /PRNewswire/ — Young physician investigators interested in a career in research are encouraged to submit basic science or clinical research abstracts by June 17 to be considered for participation in the 15th Annual Respiratory Disease Young Investigators’ Forum October 10-13, 2019, in Chicago, IL.

The forum is designed to develop the next generation of physician-scientists by offering an invaluable opportunity to present research to a panel of national experts in respiratory medicine. The panel consists of key opinion leaders who serve as real-world examples of physician-scientists who have had an impact on respiratory medicine through their contributions in research.

“The next generation of physician-scientists will continue to make tremendous impact in human health and this forum provides feedback, advice, and guidance at the most important stage of a young investigator’s career,” said Jay Kolls, MD, Program Chair.

National Jewish Health, ranked the #1 respiratory hospital in the nation by U.S. News & World Report, is committed to developing the next generation of physician-scientists through the sponsorship of the Respiratory Disease Young Investigators’ Forum. This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

The three-day program will include networking opportunities with peers and experts, as well as formal research presentations by the 30 young investigators followed by feedback and commentary from their peers and expert faculty. Career development topics will be covered ranging from strategies for successful grant applications to transitioning from trainee to independent investigator.

Fellows and junior faculty in pulmonary medicine, allergy and immunology, pediatrics, and related programs are encouraged to apply. Thirty investigators will be selected and invited to present their research at the forum based on the following criteria: scientific importance, quality of research, enhancement of knowledge, ability to answer an important scientific question and overall presentation of the abstract.  The top three selected winners in each category will be awarded a grant to support their future research endeavors in respiratory medicine.

“It was an invaluable opportunity to present my work to an external audience. To me, the conference was one of the most important events of my pulmonary fellowship,” said Tianshi David Wu, MD, 2018 Clinical Research Winner.

More information on abstract submission guidelines, the forum agenda, and program format can be found at http://njhealth.org/YIF2019.

National Jewish Health is the leading respiratory hospital in the nation. Founded 120 years ago as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of patients with respiratory, cardiac, immune and related disorders. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care. To learn more, visit www.njhealth.org.

View original content to download multimedia:http://www.prnewswire.com/news-releases/national-jewish-health-announces-call-for-abstracts-for-respiratory-disease-young-investigators-forum-300856064.html

SOURCE National Jewish Health

Staff

Recent Posts

Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…

35 minutes ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…

35 minutes ago

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…

35 minutes ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…

35 minutes ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development…

35 minutes ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…

35 minutes ago